Abstract
To present the theme of the impacts of lung cancer screening and its impact on mortality in the smoking population. Lung cancer is the neoplasm with the highest incidence and mortality in the world. Its natural history is characterized by rapid progression and late diagnosis, which limits therapeutic options and causes low patient survival. The objective of this work is to reflect on the possibilities of increasing the number of early diagnoses in order to decrease mortality and improve survival for lung cancer. The follow-up of lung cancer with low-dose computed tomography (LDCT), for example, has been shown in the National Lung Screening Trial (NLST) and NELSON studies to increase the number of early stage diagnoses and reduce lung cancer mortality by over 20%. Screening measures have shown to be favorable for asymptomatic patients at high risk of neoplasia, contributing to a favorable prognosis. LDCT is the main screening tool, with higher sensitivity in the early detection of lung neoplasia and stage I cancer compared to chest X-ray screening. In this article, we compare the results established in each study in order to reflect on the need for investment in lung cancer screening.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
